PTH Receptor Agonists

Competitor Analysis

Publication Date	January 2009
Publisher	La Merie
Product Type	Brief
Pages	18
ISBN Number	not applicable
Product Code	LME00060

Buy this product or for assistance call +44 20 7060 7474

PDF £135.00$225 | €151

FAX Order above formats by FAX

Summary

Product description

The present Competitive Intelligence Report about Parathyroid Hormone (PTH) Receptor Agonists or PTH Analogs provides a competitor evaluation in the field of R&D projects with analogs of PTH used to stimulate the PTH receptor for the treatment of osteoporosis or other bone-related diseases as of January 2009. PTH analogs are recombinant and synthetic peptides delivered by injection, inhalation, nasal, oral and transdermal administration.

The report includes a compilation of current active projects in research and development of PTH receptor agonists. In addition, the report lists company-specific pipelines of PTH receptor agonists. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

Content

Index
- Pipeline of PTH Receptor Agonists
- Corporate PTH Receptor Agonist R&D Pipelines
- About La Merie
Corporate PTH Receptor Agonist R&D Pipelines
- Aegis Therapeutics
- Altea Therapeutics
- Asahi Kasei Pharma
- Biodel
- Chugai Pharmaceutical Co.
- Cinnagen
- Eli Lilly
- Emisphere Technologies
- GlaxoSmithKline
- Kyowa Hakko Kirin
- Manhattan Pharmaceuticals
- MDRNA
- Novartis
- NPS Pharmaceuticals
- Nycomed
- Ossogen
- Proxima Concept
- Radius Health
- Ranbaxy
- Teijin
- TransPharma
- Unigene
- USV
- Virchow Biotech
- Zelos Therapeutics
- Zosano Pharma